Is CJC-1295 / Ipamorelin legal in the United Kingdom?

The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.

CJC-1295 and ipamorelin are sold together more often than either is sold alone. The logic vendors give is real pharmacology: CJC-1295 is a growth hormone releasing hormone analogue acting at the GHRH receptor, ipamorelin is a ghrelin mimetic acting at the growth hormone secretagogue receptor, and the two receptors sit on the same pituitary somatotroph.

Mechanism: Two receptors on the same pituitary cell. CJC-1295 activates the GHRH receptor, raising the amplitude of growth hormone pulses; albumin binding through the Drug Affinity Complex extends that signal for days in the DAC version.

Regulatory history: Not approved. Neither component is an approved drug, and the combination has never been submitted or studied.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for CJC-1295 / Ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.